Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on June 15, 2023. The filing relates to an update regarding the Company's At-The-Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC, originally entered into on July 1, 2020.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the procedural aspects of a securities offering.
Material Changes and Events
- Prospectus Supplement Filed: On June 15, 2023, the Company filed a prospectus supplement under its replacement shelf registration statement (Form S-3, File No. 333-271883).
- Offering Details: The supplement covers the offering of up to $7,250,000 worth of common stock pursuant to the existing ATM Agreement.
- Legal Documentation: The report incorporates by reference the opinion and consent of the Company's counsel (Nason, Yeager, Gerson, Harris & Fumero, P.A.) regarding the validity of the shares being offered.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the standard legal disclosures associated with the securities offering. No unusual items or contingencies were reported in this document.
Key Facts for Investor Verification
- Verify the current status of the $7,250,000 ATM offering and the number of shares sold to date under the July 2020 agreement.
- Review the Company's most recent 10-Q or 10-K for actual financial performance metrics, as this 8-K contains no financial data.
- Confirm the impact of the new prospectus supplement on the Company's authorized share count and potential dilution.